Tags

Type your tag names separated by a space and hit enter

Plasma homocysteine levels and Parkinson disease: disease progression, carotid intima-media thickness and neuropsychiatric complications.
Clin Neuropharmacol. 2006 Nov-Dec; 29(6):305-11.CN

Abstract

OBJECTIVE

To determine whether plasma homocysteine (Hcy) levels are associated with clinical characteristics, neuropsychological and psychiatric manifestations and cardiovascular comorbidity in patients with Parkinson disease (PD).

BACKGROUND

Elevated Hcy levels are linked to atherosclerosis, vascular disease, depression, and dementia. Patients with PD treated with L-dopa have been shown to have elevated Hcy levels.

DESIGN/METHODS

Idiopathic PD patients were evaluated using the Unified Parkinson's Disease Rating Scale, Hoehn and Yahr stage, Parkinson Psychosis Rating Scale, Beck Depression Inventory, Frontal Assessment Battery, Mini-Mental Status Examination, and several tests for frontal type cognitive functions. Fasting blood samples were collected for the measurement of Hcy, and carotid B-mode ultrasound was performed to measure intima-media thickness of the common carotid arteries.

RESULTS

Seventy-two consecutive PD patients (46 men; average age, 68.7 +/- 11.6 years; average disease duration, 7.0 +/- 4.7 years) were recruited. All but 10 patients were treated with L-dopa. The average level of Hcy was 16.4 +/- 7.8 micromol/L, and 38.9% of the patients had Hcy level above the reference range (>15.0 micromol/L). The Hcy levels were associated with PD duration as they were with L-dopa treatment duration but were not associated with the parameters of disease severity or with L-dopa dose. The Hcy levels were associated neither with the common carotid intima-media thickness nor with cardiovascular morbidity. No association was found between Hcy and the neuropsychiatric features of PD such as depression, cognitive performance, or psychosis.

CONCLUSIONS

Hyperhomocystinemia is common in L-dopa-treatedPD patients but was not associated with neuropsychological complications (depression, dementia, and cognitive decline associated with frontal lobe functioning or psychosis), enhanced disease severity, or vascular comorbidity.

Authors+Show Affiliations

Department of Neurology and Parkinson's Disease and Movement Disorders Clinic, Chaim Sheba Medical Center, Tel Hashomer, Israel. shassin@post.tau.ac.ilNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article

Language

eng

PubMed ID

17095893

Citation

Hassin-Baer, Sharon, et al. "Plasma Homocysteine Levels and Parkinson Disease: Disease Progression, Carotid Intima-media Thickness and Neuropsychiatric Complications." Clinical Neuropharmacology, vol. 29, no. 6, 2006, pp. 305-11.
Hassin-Baer S, Cohen O, Vakil E, et al. Plasma homocysteine levels and Parkinson disease: disease progression, carotid intima-media thickness and neuropsychiatric complications. Clin Neuropharmacol. 2006;29(6):305-11.
Hassin-Baer, S., Cohen, O., Vakil, E., Sela, B. A., Nitsan, Z., Schwartz, R., Chapman, J., & Tanne, D. (2006). Plasma homocysteine levels and Parkinson disease: disease progression, carotid intima-media thickness and neuropsychiatric complications. Clinical Neuropharmacology, 29(6), 305-11.
Hassin-Baer S, et al. Plasma Homocysteine Levels and Parkinson Disease: Disease Progression, Carotid Intima-media Thickness and Neuropsychiatric Complications. Clin Neuropharmacol. 2006 Nov-Dec;29(6):305-11. PubMed PMID: 17095893.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Plasma homocysteine levels and Parkinson disease: disease progression, carotid intima-media thickness and neuropsychiatric complications. AU - Hassin-Baer,Sharon, AU - Cohen,Oren, AU - Vakil,Eli, AU - Sela,Ben-Ami, AU - Nitsan,Zeev, AU - Schwartz,Roseline, AU - Chapman,Joab, AU - Tanne,David, PY - 2006/11/11/pubmed PY - 2007/1/17/medline PY - 2006/11/11/entrez SP - 305 EP - 11 JF - Clinical neuropharmacology JO - Clin Neuropharmacol VL - 29 IS - 6 N2 - OBJECTIVE: To determine whether plasma homocysteine (Hcy) levels are associated with clinical characteristics, neuropsychological and psychiatric manifestations and cardiovascular comorbidity in patients with Parkinson disease (PD). BACKGROUND: Elevated Hcy levels are linked to atherosclerosis, vascular disease, depression, and dementia. Patients with PD treated with L-dopa have been shown to have elevated Hcy levels. DESIGN/METHODS: Idiopathic PD patients were evaluated using the Unified Parkinson's Disease Rating Scale, Hoehn and Yahr stage, Parkinson Psychosis Rating Scale, Beck Depression Inventory, Frontal Assessment Battery, Mini-Mental Status Examination, and several tests for frontal type cognitive functions. Fasting blood samples were collected for the measurement of Hcy, and carotid B-mode ultrasound was performed to measure intima-media thickness of the common carotid arteries. RESULTS: Seventy-two consecutive PD patients (46 men; average age, 68.7 +/- 11.6 years; average disease duration, 7.0 +/- 4.7 years) were recruited. All but 10 patients were treated with L-dopa. The average level of Hcy was 16.4 +/- 7.8 micromol/L, and 38.9% of the patients had Hcy level above the reference range (>15.0 micromol/L). The Hcy levels were associated with PD duration as they were with L-dopa treatment duration but were not associated with the parameters of disease severity or with L-dopa dose. The Hcy levels were associated neither with the common carotid intima-media thickness nor with cardiovascular morbidity. No association was found between Hcy and the neuropsychiatric features of PD such as depression, cognitive performance, or psychosis. CONCLUSIONS: Hyperhomocystinemia is common in L-dopa-treatedPD patients but was not associated with neuropsychological complications (depression, dementia, and cognitive decline associated with frontal lobe functioning or psychosis), enhanced disease severity, or vascular comorbidity. SN - 0362-5664 UR - https://www.unboundmedicine.com/medline/citation/17095893/Plasma_homocysteine_levels_and_Parkinson_disease:_disease_progression_carotid_intima_media_thickness_and_neuropsychiatric_complications_ L2 - https://doi.org/10.1097/01.WNF.0000236763.16032.60 DB - PRIME DP - Unbound Medicine ER -